Genmab Reports Phase 2 Data Showing Over Two-Year Median Survival
The company reported median overall survival outcomes with petosemtamab plus pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma.
The company reported median overall survival outcomes with petosemtamab plus pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma.